Please login to the form below

Not currently logged in
Email:
Password:

Allergan acquires Vicept

Allergan has entered into an agreement to buy privately-owned Vicept Therapeutics

California-based pharmaceutical firm Allergan is set to acquire privately-owned Vicept Therapeutics for an undisclosed sum.

The agreement, which is expected to be finalised in the third quarter of 2011, includes a $75m cash upfront payment and up to $200m of milestone payments.

Dr Scott M Whitcup, executive vice president and chief scientific officer of Allergan, said: "The acquisition of Vicept Therapeutics will further enhance our dermatology research and development pipeline, and matches our corporate strategy and long-standing commitment to patients suffering from skin disorders."

Vicept Therapeutics' lead investigational product is V-101, a topical cream for the treatment of the erythema associated with rosacea, which has achieved positive results in two randomised, placebo-controlled phase II studies.

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics